Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

Condition:   PCNSL Interventions:   Drug: Zanubrutinib;   Drug: Rituximab;   Drug: Methotrexate;   Drug: Temozolomide Sponsor:   Ruijin Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials